• News Archive
  • Simaster
  • Webmail
  • Directory
  • Crisis Center
  •  English
    • Indonesia
Universitas Gadjah Mada Universitas Gadjah Mada Universitas Gadjah Mada Universitas Gadjah Mada
  • Education
    • Doctoral dissertation
    • Inauguration of Professor
    • Graduation
  • Achievement
  • Research and Innovation
    • Research
    • Innovation
  • Campus Info
    • Cooperation
    • Seminar and Workshop
    • Student Community Service Program
    • Other
  • News Report
  • Home
  • News Report
  • GeNose Innovation Steps Up to the Diagnostic Test Phase

GeNose Innovation Steps Up to the Diagnostic Test Phase

  • 26 October 2020, 18:26 WIB
  • By: Natasa Adelayanti
  • 5332
Alat Deteksi Covid-19 Buatan UGM Masuk Tahap Uji Diagnostik

GeNose C19 or Gadjah Mada Electronic Nose is the newest medical device innovation designed by UGM to detect Covid-19 symptoms only using people's breath rapidly. The tool developed by prof. Dr. Eng. Kuwat Triyana, M.Sc., and the team are currently proceeding to the diagnostic test phase before being mass-produced at the end of the year. "We want to set the price cheaper so that we can achieve the social value to help the society in overcoming Covid-19," Kuwat told reporters. After signing the memorandum of understanding for the GeNose C19 diagnostic test cooperation between UGM and Sardjito Hospital on Monday (26/10) at Sardjito Hospital Training Room, he conveyed this information.

He revealed that this tool had been permitted by the Ministry of Health to promptly undergo diagnostic tests at nine partner hospitals, Dr. Sardjito. The diagnostic test design was cross-sectional and triple blinded. Meanwhile, the subjects' recruitment is multicenter consecutive sampling until balanced sample size is achieved between the positive Covid-19 and Covid-19 negative groups. In the initial stages of implementing GeNose C19, it will run as a Covid-19 screening tool. As it is being evaluated for accuracy, sensitivity, and specificity, it can hopefully be enhanced to a Covid-19 diagnostic tool equivalent to a swab / PCR.

dr. Dian Kesumapramudya Nurputra, PhD., another member of the research team, said that each patient would take a breath sample and a nasopharyngeal swab sample in this diagnostic test simultaneously. She has a target estimation of about 1,500 samples tested for three weeks, 10 percent of which were Covid-19 positive patients. "We do not know whether the patient samples taken were positive or negative, so there would be no aberration in the diagnostic test study," she said.

She added that this tool could be distributed commercially by the end of the year if the testing process, scaling up, and further innovations were conducted. "I believe this is the result of multidisciplinary cooperation between scientists," she added.

UGM Chancellor, Prof. Ir. Panut Mulyono, M.Eng, D.Eng., expressed his appreciation for the performance and contribution of Dr. Sardjito in conducting the GeNose C19 diagnostic test. "We genuinely hope that all parties can give support to the development of this innovative GeNose C19 product. Hence, the tool can be immediately used to alleviate and accelerate the handling of the Covid-19 pandemic as well as to recover Indonesia's economy," he hoped.

As is known, GeNose C19 is the first innovation in Indonesia to detect Covid-19 by breath sample that is next proceeded to the cloud computing system to obtain real-time diagnosis results. GeNose C19 can also run in parallel through a centralized diagnostic process so that data validity can be maintained for all connected devices. GeNose C19 had undergone a profiling test at the Bhayangkara Polda Yogyakarta Hospital and the Bambanglipuro Covid-19 Special Field Hospital, Bantul, with a system accuracy of more than 95 percent.

In its implementation, GeNose C19 is expected to stop the Covid-19 transmission with the advantage of a lower cost per test. Because the test result is known to be more instant, it also can expedite the isolation decision. This electronic-based tool is easy to mass-produce because it uses parallel and massive Artificial Intelligence (AI) data analysis and has high specificity and sensitivity.

Author: Gusti Grehenson
Translator: Natasa A

Related News

  • Sri Sultan Carries Out the Trials of UGM Covid-19 Diagnosis Tool

    Monday,12 October 2020 - 20:08
  • UGM Innovation: GeNose Can Detect Covid-19 Less Than 2 Minutes

    Friday,25 September 2020 - 15:57
  • UGM Scientists Improving GeNose Breathalyzer System

    Monday,22 February 2021 - 9:53
  • UGM Innovation: GeNose, Covid-19 Detection through Breathing

    Monday,14 September 2020 - 19:43
  • Note these T&C before Conducting GeNose Test during Ramadan

    Tuesday,13 April 2021 - 10:57

News Releases

  • Geography Alumna’s Aromatic Telon Oil Habbie Named 2023 Indonesia Brand Champion 03 February 2023
    Novita Anggraeni, an alumna of the UGM Faculty of Ge
    Salma
  • Bimasakti UGM Kicks Off Hybrid Technology Research 03 February 2023
    Bimasakti UGM has started researching hybrid technol
    Salma
  • 18,964 UGM Students Receive Scholarships, Director of Student Affairs Says 20 January 2023
    Universitas Gadjah Mada (UGM) annually allocates hundreds
    Salma
  • Prof. Budi Setiadi Daryono Recounts Origin of His Apple Melon Cultivar 'Hikapel' 16 January 2023
    In 2012, a team of researchers from the UGM Facult
    Salma
  • UGM Graduate Fajar Kelana Named Top 20 International James Dyson Award Winner 13 January 2023
    Fajar Sidik Abdullah Kelana, an alumnus of UGM and
    Salma

Event

No latest event at this time

Universitas Gadjah Mada
UNIVERSITAS GADJAH MADA
Bulaksumur Yogyakarta 55281
   info@ugm.ac.id
   +62 (274) 588688
   +62 (274) 565223
   +62 811 2869 988

PARTNERSHIP

  • Alumni
  • International Affairs

ABOUT UGM

  • Rector's Welcome
  • History
  • Vission and Mission
  • The Board of Executive
  • Management

VISIT UGM

  • Campus Map
  • Event

REGISTRATION

  • Undergraduate
  • Graduate
  • Vocational School
  • Professional Program
  • International Program

© 2023 Universitas Gadjah Mada

PRIVACY POLICYCONTACT